New horizons in R/R follicular lymphoma: Focus on risk stratification and managing the practicalities of CAR T-cell therapy



Disclaimer

- Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions
- The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use
- No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health and touchIME activities
- USF Health and touchIME accept no responsibility for errors or omissions







Dr Peter Riedell UChicago Medicine Chicago, IL, USA

Dr Nilanjan Ghosh Atrium Health Levine Cancer Institute Charlotte, NC, USA



Utilizing prognostic factors in FL to identify high-risk patients and guide treatment decisions

Dr Peter Riedell

UChicago Medicine Chicago, IL, USA





Challenges for clinical decision making in FL

Key clinical considerations for patients with FL

- Timing of treatment initiation
- Optimal treatment choice: first/later lines



- Potential for histological transformation
- Presence of POD24

- Meaningful remission
- Palliation of symptoms
- Prolongation of life



Cumulative toxicities and impact on patient mortality/morbidity

Given the variable clinical behaviour of FL, the decision of **when** to treat is as important as **how** to treat. There are several prognostic indices, but none dictate the timing or type of treatment at the level of an individual patient



Models used to predict survival in patients with FL¹

Risk factors

Pre-treatment prognostic models

Prognosis

5-yr OS: 91 vs 78 vs 53%²

3-yr OS: 99 vs 96 vs 84%

5-yr PFS: 69 vs 55 vs 37%

5-yr FFS: 77 vs 38%

Risk stratification

Low vs int vs high

Low vs int vs high

Low vs int vs high

Low vs high

Pre-treatment

>60 years

- Ann Arbor stage: III–IV 2.
- Affected nodal regions: >4 3.
- Hb: <12 g/dL 4.
- Serum LDH: >ULN
- Largest node: >6 cm
- Bone marrow involvement
- β2-microglobulin levels* 8.
- Mutational profile[†] 9.
- 10. ECOG PS >1

Post-treatment prognostic model Post-treatment <24 vs >24 months 5-yr OS: 50 vs 90% **POD24** POD24 PET scan (positive)[‡]

1 - 5

7,8

1, 4, 6-8

FLIPI-H, 9, 10

*FLIPI-2, >ULN; PRIMA-PI, >3 g/L. [†]Mutations in *EP300, CREBBP, CARD11, MEF2B, EZH2, ARID1A* and *FOX01.*

[‡]A positive PET scan at the end of treatment is indicative of a poor prognosis.

ECOG PS, Eastern Cooperative Oncology Group performance status; FFS, failure-free survival; FL, follicular lymphoma;

Model

FLIPI-1

FLIPI-2

PRIMA-PI

m7-FLIPI

FLIPI, Follicular Lymphoma International Prognostic Index; H, high risk; Hb, haemoglobin; int, intermediate; LDH, lactate dehydrogenase;

m7, including the mutation status of seven genes; OS, overall survival; PET, positron emission tomography; PFS, progression-free survival;

POD24, progression of disease within 24 months; PRIMA-PI, Primary Rituximab and Maintenance Study Prognostic Index; ULN, upper limit of normal; yr, year.

1. Gupta G, et al. Am J Blood Res. 2022;12:105–24; 2. Solal-Celigny P, et al. Blood. 2004;104:1258–65.



Latest evidence for CAR T-cell therapies in R/R FL, their place in the treatment sequence and considerations for patient selection

Dr Peter Riedell

UChicago Medicine Chicago, IL, USA





NCCN 2023 guidelines for treating R/R FL

Preferred regimens for sufficiently fit patients

- Bendamustine + obinutuzumab or rituximab[†]
- CHOP + obinutuzumab or rituximab

2L*


- CVP + obinutuzumab or rituximab
- Lenalidomide + rituximab



*The same regimens are used in the first line; generally, a first-line therapy is not repeated. [†]Not recommended if treated with prior bendamustine. [‡]Third-line and subsequent systemic therapy includes second-line therapies that have not been used previously. [§]In alphabetical order. CAR, chimeric antigen receptor; CD, cluster of differentiation; CHOP, cyclophosphamide + doxorubicin + vincristine + prednisone; CVP, cyclophosphamide + vincristine + prednisone; EZH2, enhancer of zeste homolog 2; L, line; NCCN, National Comprehensive Cancer Network; PI3K, phosphoinositide 3 kinase; R/R FL, relapsed or refractory follicular lymphoma. NCCN. B-cell lymphomas. V6.2023. Available at: www.nccn.org (accessed 8 November 2023).



CAR T-cell therapy to treat R/R FL: Efficacy



Direct comparisons between trials should not be made due to differences in trial design.

*Eligible for activity analysis, n=86. [†]At 18 months. [‡]RiR: at 9 months; PFS: at 12 months. [§]≥3 prior lines of treatment. ^{II}Median not reached; mFU (RiR): 16.6 months; mFU (PFS): 17.5 months. Axi-cel, axicabtagene ciloleucel; CAR, chimeric antigen receptor; CR, complete response; DoR, duration of response; FLIPI-H, Follicular Lymphoma International Prognostic Index – high risk; FU, follow-up; GELF, Groupe d'Étude des Lymphomes Folliculaires; L, lines of prior therapy; Liso-cel, lisocabtagene maraleucel; m, median; mo, months; N/R, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; POD24, progression of disease within 24 months; RiR, remaining in response; R/R FL, relapsed or refractory follicular lymphoma; Tisa-cel, tisagenlecleucel. 1. Jacobson CA, et al. *Lancet Oncol*. 2022;23:91–103; 2. Neelapu SS. et al. *Blood*. 2022;140(Suppl. 1):10380–3; 3. Fowler NH, et al. *Nat Med*. 2022;28:325–32; 4. Dreyling M, et al. *Blood*. 2022;140(Suppl. 1):1459–63; 5. Morschhauser F, et al. *Hematol Oncol*. 2023;41(Suppl. 2):877–80.



 Managing the practicalities of CAR T-cell therapies in the clinic: Focus on safety and the multidisciplinary team approach


Dr Peter Riedell

UChicago Medicine Chicago, IL, USA





• CAR T-cell therapy to treat R/R FL: Safety



Direct comparisons between trials should not be made due to differences in trial design.

*Safety set, N=148. ⁺Multisystem organ failure. [‡]Safety set ≥2 prior lines of treatment. [§]Neutropenia, most common haematologic adverse event.

"Grade 5 macrophage activation syndrome.

Axi-cel, axicabtagene ciloleucel; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; gr, grade; Liso-cel, lisocabtagene maraleucel; NE, neurological events; R/R FL, relapsed or refractory follicular lymphoma; TEAE, treatment-emergent adverse event; Tisa-cel, tisagenlecleucel.

1. Jacobson CA, et al. Lancet Oncol. 2022;23:91–103; 2. Fowler NH, et al. Nat Med. 2022;28:325–32; 3. Morschhauser F, et al. Hematol Oncol. 2023;41(Suppl. 2):877–80.



Multidisciplinary management of side effects associated with CAR T-cell therapies^{1–5}

